Altimmune Inc ALT:NASDAQ

RT Quote | NASDAQ | USD
Last | 03/04/21 EST
13.18quote price arrow down-1.19 (-8.28%)
Volume
2,158,611
52 week range
2.50 - 35.10

...

Loading . . .

KEY STATS

  • Open14.29
  • Day High14.29
  • Day Low12.22
  • Prev Close13.18
  • 52 Week High35.10
  • 52 Week High Date07/20/20
  • 52 Week Low2.50
  • 52 Week Low Date03/10/20
  • Market Cap489.64M
  • Shares Out37.15M
  • 10 Day Average Volume1.53M
  • Dividend-
  • Dividend Yield-
  • Beta1.70
  • 1 Year % Change362.46

RATIOS/PROFITABILITY

  • EPS (TTM)-2.02
  • P/E (TTM)-6.51
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-48.072M
  • ROE (MRQ)-34.14%
  • Revenue (MRQ)6.45M
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-659.41%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date05/11/2021
  • Ex Div Date02/06/2017
  • Div Amount2.91
  • Split Date-
  • Split Factor-

Latest Altimmune Inc News

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Altimmune Inc is a clinical-stage immunotherapeutics company. The Company is focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The Company’s product candidates include ALT-801, HepTcell, ALT-702, NasoVAX and NasoShield. HepTcell is a synthetic peptide immunotherapeutic candidate designed to break immune tolerance in chronic Hepatitis B infection. ALT-702, a TLR7/8 agonist conjugate, is a tumor...
Mitchel Sayare Ph.D.
Chairman
Vipin Garg Ph.D.
President
William Brown CPA
Chief Financial Officer
Address
910 Clopper Rd Ste 201S
Gaithersburg, MD
20878-1361
United States